Substance/medication-induced (S/M-NCD) is the diagnosis for cognitive impairment that begins during or shortly after substance intoxication, withdrawal, or medication exposure and persists beyond the expected duration of those acute states. It sits within the broader neurocognitive disorders (NCDs) chapter alongside , vascular NCD, and NCD, and it forces the clinician to distinguish a potentially reversible toxic process from a degenerative one. Alcohol is the prototypical cause, but sedative-hypnotics, inhalants, methamphetamine, and several prescribed medications (anticholinergics, chemotherapeutics, immunosuppressants) can produce the same picture. The diagnosis hinges on temporal linkage to the agent, persistence beyond expected acute effects, and exclusion of delirium and other NCDs. The clinical bottom line: identify the agent, confirm abstinence or discontinuation, and re-assess cognition over weeks to months before assigning permanence.
Population-level prevalence is hard to pin down because S/M-NCD is frequently misclassified as primary or as a residual feature of substance use disorder. Alcohol-related cognitive impairment dominates the case mix in most clinical series.
Prevalence and burden
- Alcohol-related cognitive impairment is the most common cause of S/M-NCD in clinical samples and is a notable contributor to early-onset dementia in some European cohorts.[1,3]
- Cognitive impairment is reported in a substantial proportion of adults with across cohorts and instruments, with a smaller subset meeting criteria for frank dementia.[1,3]
- Methamphetamine and chronic inhalant use are the next most frequently implicated illicit substances; benzodiazepine-related NCD is increasingly recognized in older adults on long-term use.[3-4]
Demographics
- Onset clusters in midlife (40s–60s) for alcohol-related cases, earlier (20s–40s) for methamphetamine and inhalant cases, and later (>65) for medication-induced cases.[2-3]
- Male predominance follows the sex distribution of the underlying substance use disorder; medication-induced cases show no clear sex skew.[3]
- Lower educational attainment, head injury, malnutrition (particularly thiamine deficiency), and hepatic dysfunction increase risk in alcohol-related cases.[1-2]
Comorbidity
Mechanisms vary by agent and frequently overlap within a single patient. The shared pathway is sustained neurotoxic exposure leading to neuronal loss, white matter injury, or sustained receptor-level dysregulation that outlasts the drug's pharmacokinetics.
Alcohol-related mechanisms
- Direct ethanol neurotoxicity produces cortical and cerebellar atrophy, with frontal lobes and the corpus callosum disproportionately affected.[1-2]
- Thiamine deficiency drives Wernicke- through damage to mammillary bodies, the medial dorsal thalamus, and periaqueductal gray.[2,5]
- Hepatic dysfunction contributes via chronic hyperammonemia, manganese deposition in the basal ganglia, and altered GABA-A signaling.[2]
- Recurrent withdrawal episodes are independently associated with hippocampal injury through glutamate excitotoxicity.[2-3]
Other substance mechanisms
- Methamphetamine causes with reductions in striatal dopamine transporter density and frontal hypometabolism on FDG-PET.[3,6]
- Inhalants (toluene, n-hexane) produce diffuse white matter demyelination visible as T2 hyperintensities and a characteristic loss of gray-white differentiation.[3]
- Chronic benzodiazepine use may impair encoding and speed; whether structural injury occurs after discontinuation remains contested.[4,7]
- Opioid-related NCD is rare in isolation and usually reflects anoxic injury from overdose or concurrent infectious or toxic insults.[3]
Medication-induced mechanisms
- burden in older adults is associated with both incident cognitive impairment and accelerated decline in those with subclinical Alzheimer pathology.[8-9]
- Cancer chemotherapy ("chemo brain") may persist after treatment and has been linked to white matter changes, neuroinflammation, and hippocampal neurogenesis suppression.[10]
- Calcineurin inhibitors (tacrolimus, cyclosporine), interferons, and chronic high-dose corticosteroids produce reversible-to-persistent cognitive syndromes in solid-organ transplant and oncology populations.[10-11]
S/M-NCD is diagnosed when cognitive impairment is temporally linked to a substance or medication, persists beyond the expected duration of acute intoxication or withdrawal, and is not better explained by another NCD or by delirium. The core DSM-5-TR framework mirrors the major and mild NCD criteria, with substance-specific etiologic anchors.
Core DSM-5-TR criteria
- Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, social cognition), based on history and standardized testing.[12]
- The impairment does not occur exclusively during delirium and persists beyond the usual duration of intoxication and acute withdrawal.[12]
- The substance, medication, or its duration and extent of use are capable of producing the observed neurocognitive impairment.[12]
- The temporal course of cognitive deficits is consistent with the timing of substance, medication, or withdrawal exposure.[12]
- The disorder is not better explained by another medical condition or another mental disorder.[12]
Severity
- Mild NCD: modest decline that does not interfere with capacity for independence in everyday activities; greater effort, compensatory strategies, or accommodation may be required.[12]
- Major NCD: substantial decline that interferes with independence in everyday activities (e.g., paying bills, managing medications).[12]
Specifiers
- Specify the substance: alcohol, sedative-hypnotic/anxiolytic, inhalant, other (or unknown).[12]
- For alcohol-related major NCD, further specify amnestic-confabulatory type (Korsakoff phenotype) versus nonamnestic-confabulatory type.[12]
- Persistent specifier applies when neurocognitive impairment continues well beyond the period of acute intoxication and withdrawal.[12]
places these conditions under chapter 06 "Mental, behavioural or neurodevelopmental disorders due to use of [substance]" with a distinct "residual neurocognitive disorder" qualifier rather than as a unified neurocognitive category.[13]
The clinical picture depends on the agent, but a few features recur: executive dysfunction out of proportion to memory loss early on, gait or coordination changes when alcohol or inhalants are involved, and partial recovery during sustained abstinence. The course is rarely the steady progressive arc of Alzheimer disease.
Alcohol-related presentations
- Frontal-executive impairment dominates: working memory, set-shifting, inhibition, and judgment are affected before declarative memory in many patients.[1-2]
- Cerebellar signs (gait ataxia, dysarthria, intention tremor) co-occur in patients with significant cerebellar atrophy.[2]
- Korsakoff syndrome presents as severe anterograde amnesia with relative preservation of other cognitive domains and variable , often emerging from inadequately treated Wernicke encephalopathy.[2,5]
- Confabulation is the production of fabricated, distorted, or misinterpreted memories without conscious intent to deceive; it is most prominent early in Korsakoff syndrome.[5]
Stimulant-related presentations
- Methamphetamine-related NCD shows executive dysfunction, psychomotor slowing, and decision-making deficits, often with persistent psychotic features.[3,6]
- Cognitive deficits can persist for 12 months or longer after sustained abstinence, with partial recovery typical.[6]
Sedative-hypnotic presentations
- Chronic benzodiazepine users commonly show deficits in visuospatial processing, attention, and verbal memory.[4,7]
- Symptoms may improve substantially within 6 months of discontinuation, although recovery is incomplete in a sizable minority.[7]
Inhalant and medication-induced presentations
- Toluene-induced leukoencephalopathy produces cognitive slowing, , and cerebellar signs.[3]
- Anticholinergic-induced impairment in older adults presents as attentional and memory deficits that improve with deprescribing, though residual deficits are common in heavy chronic exposure.[8-9]
- Cancer-treatment-related cognitive impairment commonly involves processing speed, working memory, and executive function and may persist for years post-treatment.[10]
FRONTAL
Frontal lobe signs in alcohol-related NCD — Forgetting working tasks, Reduced inhibition, Organization deficits, Naming and verbal fluency loss, Trail-making slowing, Apathy, Loss of insight.
The differential is large because cognitive impairment in a person who uses substances is rarely monoetiologic. The required move is to exclude treatable mimics first, then distinguish S/M-NCD from primary NCDs, then sort co-occurring contributors by likely magnitude.
Acute and reversible mimics
- Delirium is excluded by demonstrating that cognitive impairment persists beyond the period of acute intoxication or withdrawal and is not better explained by an acute encephalopathic state.[12]
- Wernicke encephalopathy presents acutely with the classical triad of ophthalmoplegia, ataxia, and confusion; missing the diagnosis allows Korsakoff syndrome to consolidate.[5]
- Hepatic encephalopathy, uremia, hypothyroidism, and B12 deficiency must be ruled out, particularly in patients with alcohol use disorder.[2]
Primary neurocognitive disorders
- Alzheimer disease typically progresses with prominent episodic memory loss, semantic memory degradation, and an indolent course unaffected by abstinence.[14]
- Vascular NCD is suggested by stepwise decline, focal deficits, and imaging evidence of strategic infarcts or extensive small vessel disease.[14]
- Frontotemporal NCD can mimic alcohol-related frontal-executive presentations; behavioral variant FTD features early personality change and disinhibition out of proportion to substance use history.[14]
- Lewy body NCD presents with cognitive fluctuations, visual , , and REM sleep behavior disorder.[14]
Substance-related but not S/M-NCD
- Persistent substance-induced psychotic disorder, depressive disorder, or anxiety disorder may impair cognition without meeting NCD criteria.[12]
- HIV-associated NCD, hepatitis C-associated cognitive impairment, and traumatic brain injury are common comorbid contributors in substance-using populations and require their own diagnostic coding.[2-3]
| Feature | Alcohol-related NCD | Alzheimer NCD | Frontotemporal NCD | Vascular NCD |
|---|---|---|---|---|
| Onset | Midlife, after years of use | Insidious, late-life | 50s–60s | Stepwise, post-stroke |
| Dominant deficit | Executive, cerebellar | Episodic memory | Behavior, language | Variable, focal |
| Course with abstinence | Stable or improving | Progressive | Progressive | Variable |
| Imaging | Cortical/cerebellar atrophy, callosal thinning | Hippocampal/temporoparietal atrophy | Frontotemporal atrophy | Strategic infarcts, WMH |
| First-line management | Abstinence, thiamine, rehabilitation | Cholinesterase inhibitor | Symptomatic, no disease-modifying tx | Vascular risk control |
Assessment combines a careful substance and medication history, structured cognitive testing, and targeted medical workup to exclude reversible contributors. A single visit is rarely enough; serial assessment during enforced abstinence is the diagnostic gold standard.
History
- Quantify substance use using a structured tool such as or AUDIT-C for alcohol, with attention to lifetime exposure, peak use, and recency of last use.[15]
- Reconstruct the medication exposure list including over-the-counter agents, herbal supplements, and recently discontinued drugs; calculate anticholinergic burden using a validated scale such as the Anticholinergic Cognitive Burden scale.[8-9]
- Collateral history from family or caregivers is essential; patients commonly underreport use and overestimate cognitive function.[1]
- Screen for traumatic brain injury, seizures, withdrawal complications, and prior episodes of Wernicke encephalopathy.[5]
Cognitive testing
- Brief screens (, ) are starting points; the MoCA outperforms MMSE for the frontal-executive deficits typical of alcohol-related NCD.[16]
- Detailed neuropsychological testing covering executive function, episodic memory, visuospatial processing, and processing speed is the diagnostic standard when feasible.[1-2]
- Repeat testing at 4–6 weeks and again at 3–6 months of abstinence; documented improvement supports the diagnosis and informs prognosis.[2]
Laboratory workup
- Standard dementia workup: CBC, comprehensive metabolic panel, TSH, vitamin B12, folate, HIV, and syphilis serology.[14]
- Liver function tests, GGT, MCV, and carbohydrate-deficient transferrin support alcohol exposure documentation.[15]
- Urine drug screen at presentation; consider hair testing for chronic exposure.[3]
- Thiamine level is rarely useful diagnostically because of low sensitivity; empirical replacement is the standard.[5]
Imaging
- Structural MRI is preferred over CT and may show cortical atrophy, cerebellar atrophy, white matter hyperintensities, or mammillary body atrophy.[2,14]
- FDG-PET shows frontal hypometabolism in chronic methamphetamine use and a posterior temporoparietal pattern in Alzheimer disease; amyloid PET helps when AD is strongly suspected.[6,14]
- Routine functional imaging is not required for diagnosis.[14]
Do not delay empirical thiamine in any patient with suspected alcohol-related cognitive impairment; oral repletion is inadequate for established or suspected Wernicke encephalopathy, which requires high-dose parenteral thiamine.[5]
There is no disease-modifying pharmacotherapy for S/M-NCD itself. Management centers on removing the offending agent, treating the underlying substance use disorder, correcting nutritional and metabolic contributors, and providing cognitive rehabilitation.
Pharmacotherapy
- Strong evidence supports high-dose parenteral thiamine for suspected or established Wernicke encephalopathy: thiamine 500 mg IV TID for 2–3 days, followed by 250 mg IV or IM daily for 5 days, then oral maintenance.[5,17]
- Evidence suggests treating the underlying alcohol use disorder with naltrexone 50 mg PO QD, acamprosate 666 mg PO TID, or disulfiram 250 mg PO QD to support abstinence; choice depends on hepatic function, renal function, and adherence likelihood.[18-19]
- Limited evidence suggests that such as donepezil 5 mg PO QD may modestly improve cognition in alcohol-related NCD, but trials are small and benefits inconsistent; routine use is not recommended.[20]
- Memantine has been studied in alcohol-related NCD with mixed results and is not a guideline-endorsed treatment.[20]
- For medication-induced NCD, deprescribing the offending agent is the primary intervention; substitute lower-burden alternatives where possible.[8-9]
Psychotherapy
- Evidence suggests that cognitive rehabilitation programs targeting attention, executive function, and compensatory strategies produce measurable functional gains in alcohol-related NCD.[2,21]
- and relapse prevention should be adapted for cognitive impairment, with simpler language, repetition, and caregiver involvement.[1]
- 12-step facilitation, cognitive-behavioral therapy, and contingency management have evidence in the underlying substance use disorder, with cognitive impairment requiring program modification.[18-19]
Neuromodulation
- No neuromodulation therapy has established efficacy for S/M-NCD. Repetitive TMS has been investigated for craving reduction in alcohol and stimulant use disorders, with cognitive endpoints secondary and inconsistent.[22]
Adjunctive
- Nutritional repletion (thiamine, folate, B12, protein-calorie status) is mandatory in alcohol-related cases.[5,17]
- Treat comorbid mood, anxiety, and psychotic disorders aggressively; cognitive impairment frequently improves when depression remits.[1-2]
- Vascular risk factor management (hypertension, diabetes, hyperlipidemia, smoking cessation) protects against compounding cognitive injury.[14]
- Occupational therapy, supervised living arrangements, and caregiver education for major NCD severity.[1]
Cognitive recovery in alcohol-related NCD continues for at least 12 months with sustained abstinence; avoid making permanent placement decisions before this window has elapsed.[2]
| Intervention | Evidence base/Comparator | Benefits | Harms | Certainty | Notes |
|---|---|---|---|---|---|
| Sustained abstinence (alcohol) | Prospective cohorts vs continued use | Partial-to-substantial cognitive recovery over 6–12 months | Withdrawal risk without medical support | moderate | Cornerstone intervention; effect size largest in first 3 months [1-2] |
| High-dose parenteral thiamine | RCT and observational data in Wernicke encephalopathy | Prevents progression to Korsakoff syndrome; reverses ocular signs | Rare anaphylaxis with IV bolus | moderate | 500 mg IV TID for 2–3 days, then taper [5,17] |
| Naltrexone or acamprosate for AUD | Multiple RCTs vs placebo | Reduces heavy drinking days, supports abstinence | Naltrexone: hepatotoxicity, GI; acamprosate: diarrhea | high | Indirect cognitive benefit through sustained abstinence [18] |
| Deprescribing anticholinergics and | Observational cohorts and small RCTs | Cognitive improvement in older adults within weeks to months | Withdrawal phenomena, rebound symptoms | moderate | Taper slowly; reassess at 3 and 6 months [4,7-8] |
| Cholinesterase inhibitors in alcohol-related major NCD | Small RCTs and open-label studies | Modest, inconsistent cognitive gains | GI effects, bradycardia | low | Not standard of care; consider when Alzheimer overlap suspected [20] |
| Cognitive rehabilitation | Small RCTs and pilot studies | Improvements in attention, executive function in motivated patients | Time and access burden | low | Adjunct to abstinence; benefit largest when combined with sobriety [21] |
| Repetitive TMS for substance use and cognition | Emerging RCTs | Reduces craving; cognitive endpoints inconsistent | Headache, scalp discomfort, rare seizure | very_low | Not approved for S/M-NCD indication; investigational [22] |
The harms picture in S/M-NCD has two faces: harms from the causative agent itself (intoxication, withdrawal, dependence, end-organ damage) and harms from the interventions used to manage the disorder. Both deserve explicit framing for patients and families.
- Continued exposure to the offending substance accelerates cognitive decline and may convert a partially reversible picture into permanent major NCD.[1-2]
- Withdrawal from alcohol, sedative-hypnotics, and benzodiazepines carries seizure and risk; abrupt discontinuation without medical supervision can be fatal.[14]
- Naltrexone is contraindicated in active opioid use and in acute hepatitis or hepatic failure; baseline LFTs are required.[18]
- Acamprosate requires renal dose adjustment and is contraindicated in severe renal impairment.[18]
- Disulfiram should not be initiated in patients who cannot reliably abstain or who have significant cardiac, hepatic, or cognitive disease; the disulfiram-ethanol reaction can be life-threatening.[18]
- Cholinesterase inhibitor evidence in alcohol-related NCD is limited, and gastrointestinal and cardiac adverse effects are non-trivial in malnourished, frail patients.[20]
- Most studies of cognitive recovery have short follow-up (3–12 months), enroll relatively young samples, and exclude patients with severe comorbid medical illness, limiting generalizability to older, sicker clinical populations.[1-2]
- Publication bias likely overstates the magnitude of recovery; null trials of cognitive rehabilitation and adjunctive pharmacotherapy may be under-reported.[21]
- The diagnostic category itself is heterogeneous; lumping inhalant, alcohol, methamphetamine, and medication-induced presentations into one entity obscures agent-specific trajectories.[3]
Cognitive impairment from substances and medications presents differently across the life span, and identification of the responsible agent often depends on the population's exposure profile.
Older adults
- Anticholinergic and benzodiazepine burden are the dominant medication-induced contributors; review with an explicit deprescribing framework at every encounter.[4,7-9]
- Alcohol use is under-recognized in older adults; screen with the AUDIT-C and ask explicitly about quantity and frequency rather than relying on patient-volunteered concern.[2,15]
- Falls, polypharmacy, and frailty raise the harm-benefit threshold for any psychotropic; the Beers Criteria identify high-risk agents.[8]
Perinatal
- Maternal alcohol, methamphetamine, and inhalant use in pregnancy cause fetal neurodevelopmental injury rather than maternal S/M-NCD per se, but maternal cognitive impairment can co-occur and complicate care planning.[3]
- Benzodiazepine and opioid tapering in pregnancy requires obstetric and addiction-medicine coordination; abrupt discontinuation risks fetal distress.[14]
Pediatric and adolescent
- Inhalant abuse is disproportionately a problem of adolescents and young adults; cognitive sequelae from chronic toluene exposure include leukoencephalopathy with cerebellar ataxia and frontal-executive impairment.[3]
- Chronic cannabis use in adolescence is associated with attention and executive deficits that may persist after abstinence; whether this rises to the threshold of S/M-NCD remains debated.[3]
Comorbid medical illness
- Hepatic encephalopathy can mimic or coexist with alcohol-related NCD; ammonia and hepatic synthetic function should be checked before attributing all cognitive change to alcohol toxicity.[2,14]
- HIV-associated neurocognitive disorder, hepatitis C, and chronic kidney disease compound substance-related cognitive injury and complicate medication selection.[1,14]
Cultural and social considerations
Prognosis depends almost entirely on whether the patient achieves and sustains abstinence (or discontinuation in the medication-induced case). Trajectories range from near-complete recovery to permanent major NCD.
Course patterns
- Mild S/M-NCD with sustained abstinence frequently shows substantial cognitive recovery over 3–12 months, with the largest gains in the first 3 months.[1-2]
- Major S/M-NCD with sustained abstinence shows partial recovery in many cases; full recovery is uncommon when impairment is severe at baseline.[1-2]
- Persistent or progressive impairment is the rule with continued substance use; mortality from medical complications and accidents is elevated.[1-2]
- Korsakoff syndrome, once established, typically persists; only a minority of patients recover to a functional baseline.[5]
Predictors of recovery
- Younger age, shorter duration of heavy use, and absence of severe medical comorbidity predict better cognitive outcome.[1-2]
- Higher educational attainment (cognitive reserve) and supportive social environment improve functional recovery.[2]
- Female sex is associated with greater alcohol-related cognitive injury per gram-year of exposure, though recovery trajectories with abstinence are comparable.[2]
Mortality and functional outcome
- All-cause mortality is substantially elevated compared with the age-matched population in severe alcohol-related NCD, driven by accidents, suicide, hepatic disease, and cardiovascular events.[1-2]
- Independent living is generally preserved in mild S/M-NCD; supported living or institutional care is commonly required in major S/M-NCD.[2]
Acute presentations are usually driven by superimposed intoxication, withdrawal, or delirium rather than the underlying NCD itself. The first triage question is whether the picture is a slow, persistent deficit (the NCD) or a fast, fluctuating one (delirium) — the latter is a medical emergency.[12,14]
Hospitalization criteria
- Acute withdrawal at risk of seizures or delirium tremens, particularly in alcohol or sedative-hypnotic use disorder.[14]
- Suspected Wernicke encephalopathy or any unexplained confusional state in a patient with heavy alcohol use; treat with parenteral thiamine before glucose.[5,17]
- New focal neurological signs, severe disorientation, or rapid cognitive decline over days to weeks, which mandate imaging and broad medical workup.[14]
- Inability to maintain safe self-care, fluid intake, or medication adherence at home.[14]
Suicide and self-harm risk
- Cognitive impairment compounds the elevated suicide risk that accompanies substance use disorders, particularly in the first weeks of abstinence.[1-2]
- Impaired judgment and disinhibition increase risk of impulsive overdose and accidental self-harm.[2]
- Screen explicitly at every visit; access to firearms and to the substance of use should be addressed with the family.[14]
Agitation management
- Treat the underlying cause (withdrawal, pain, delirium) rather than reflexively medicating behavior.[14]
- Avoid anticholinergic agents and high-dose benzodiazepines outside of clear withdrawal indications; both worsen cognition.[8,14]
- Low-dose haloperidol or a short-term for severe agitation in delirium, with the lowest effective dose and short duration.[14]
Give parenteral thiamine before any intravenous glucose in a patient with suspected heavy alcohol use; glucose loading without thiamine can precipitate Wernicke encephalopathy.[5,17]
Several questions remain open and shape day-to-day decisions at the bedside.
Reversibility timeline
- DSM-5-TR allows the persistent specifier when impairment continues beyond the usual duration of intoxication and acute withdrawal, but the field has no consensus on how long to wait before declaring the deficit permanent.[12]
- Most experts wait 6–12 months of documented abstinence before assigning a fixed prognosis in alcohol-related cases, though high-quality evidence is lacking.[2-3]
Boundary with primary dementias
- Heavy alcohol use is an established modifiable risk factor for dementia, and distinguishing pure alcohol-related NCD from Alzheimer disease with alcohol contribution can be impossible in older adults.[1-2]
- Biomarker testing (CSF amyloid/tau, amyloid PET) helps when an Alzheimer process is suspected, but access is limited and findings can coexist.[14]
Benzodiazepines and long-term cognitive harm
- Observational studies link chronic benzodiazepine use to cognitive decline and possibly to dementia incidence, but residual confounding by indication (anxiety and insomnia as dementia prodromes) limits causal claims.[4,7]
- Guidelines converge on minimizing duration and dose, but disagree on whether established long-term users with stable function should be deprescribed.[4,7]
Cannabis and cognition
- Heavy, early-onset, sustained cannabis use is associated with cognitive deficits, but whether these meet S/M-NCD threshold and whether they persist with abstinence remain actively debated.[3]
- DSM-5-TR does not list cannabis among the prototypical agents; case-level attribution requires careful exclusion of other contributors.[12]
Chemotherapy-related cognitive impairment
- S/M-NCD requires cognitive impairment that persists beyond the expected duration of intoxication and acute withdrawal, attributable to a substance or medication.[12]
- Alcohol is the most common cause; sedative-hypnotics, inhalants, methamphetamine, and certain prescribed medications are the other major culprits.[1-3]
- Give parenteral thiamine before glucose in suspected Wernicke encephalopathy.[5,17]
- Wernicke triad: encephalopathy, oculomotor dysfunction (nystagmus, ophthalmoplegia), and gait ataxia; full triad is present in fewer than 20% of cases.[5]
- Korsakoff syndrome is characterized by severe anterograde amnesia with relative preservation of other cognitive domains, often with confabulation.[5]
- Thiamine for suspected Wernicke encephalopathy is given as 500 mg IV three times daily for at least 2–3 days, then tapered; oral replacement alone is inadequate in the acute phase.[5,17]
- Anticholinergic burden is a leading reversible cause of cognitive impairment in older adults; review medications using a tool such as the Anticholinergic Cognitive Burden scale.[8-9]
- Long-term benzodiazepine use is associated with cognitive impairment that may partially reverse with gradual taper.[4,7]
- Methamphetamine produces deficits in executive function, memory, and psychomotor speed; partial recovery occurs with sustained abstinence over 12+ months.[3,6]
- Naltrexone and acamprosate are first-line pharmacotherapy for alcohol use disorder and indirectly support cognitive recovery by sustaining abstinence.[18]
- Cholinesterase inhibitors are not routinely recommended for S/M-NCD; evidence is limited and benefits inconsistent.[20]
- Abstinence is the cornerstone of management; cognitive recovery is most likely in the first 6–12 months.[2-3]
- S/M-NCD is coded as mild or major based on functional impact, and as persistent when symptoms continue beyond expected acute effects.[12]
- Differentiating S/M-NCD from delirium turns on time course and arousal: delirium fluctuates over hours with altered arousal; NCD is steady with preserved arousal.[12,14]
No external funding. No conflicts of interest declared. Peer-review status: pending.
- 1.Ridley NJ, Draper B, Withall A. Alcohol-related dementia: an update of the evidence. Alzheimers Res Ther. 2013;5(1):3. doi:10.1186/alzrt157. PMID: 23347747.PMID: 23347747doi:10.1186/alzrt157
- 2.Oslin DW, Cary MS. Alcohol-related dementia: validation of diagnostic criteria. Am J Geriatr Psychiatry. 2003;11(4):441-447. doi:10.1097/00019442-200307000-00007. PMID: 12837673.PMID: 12837673doi:10.1097/00019442-200307000-00007
- 3.TextbookBrust JCM. Neurological Aspects of Substance Abuse. 2nd ed. Philadelphia: Elsevier Butterworth-Heinemann; 2004.
- 4.Systematic reviewCrowe SF, Stranks EK. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol. 2018;33(7):901-911. doi:10.1093/arclin/acx120. PMID: 29244060.PMID: 29244060doi:10.1093/arclin/acx120
- 5.Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455. doi:10.1016/S1474-4422(07)70104-7. PMID: 17434099.PMID: 17434099doi:10.1016/S1474-4422(07)70104-7
- 6.Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158(3):377-382. doi:10.1176/appi.ajp.158.3.377. PMID: 11229977.PMID: 11229977doi:10.1176/appi.ajp.158.3.377
- 7.Systematic reviewBarker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37-48. doi:10.2165/00023210-200418010-00004. PMID: 14731058.PMID: 14731058doi:10.2165/00023210-200418010-00004
- 8.Case-controlCoupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677. PMID: 31233095.PMID: 31233095doi:10.1001/jamainternmed.2019.0677
- 9.Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-320. doi:10.2217/1745509X.4.3.311.doi:10.2217/1745509X.4.3.311.
- 10.Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192-201. doi:10.1038/nrc2073. PMID: 17318212.PMID: 17318212doi:10.1038/nrc2073
- 11.Wijdicks EFM. Neurotoxicity of immunosuppressive drugs. Liver Transpl. 2001;7(11):937-942. doi:10.1053/jlts.2001.27475. PMID: 11699028.PMID: 11699028doi:10.1053/jlts.2001.27475
- 12.TextbookAmerican Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. Washington, DC: American Psychiatric Association Publishing; 2022.
- 13.TextbookWorld Health Organization. International Classification of Diseases, 11th Revision (ICD-11). Geneva: WHO; 2019.
- 14.Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19(9):1159-1179. doi:10.1111/j.1468-1331.2012.03784.x. PMID: 22891773.PMID: 22891773doi:10.1111/j.1468-1331.2012.03784.x
- 15.Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction. 1993;88(6):791-804. doi:10.1111/j.1360-0443.1993.tb02093.x. PMID: 8329970.PMID: 8329970doi:10.1111/j.1360-0443.1993.tb02093.x
- 16.Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x. PMID: 15817019.PMID: 15817019doi:10.1111/j.1532-5415.2005.53221.x
- 17.Galvin R, Brathen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408-1418. doi:10.1111/j.1468-1331.2010.03153.x. PMID: 20642790.PMID: 20642790doi:10.1111/j.1468-1331.2010.03153.x
- 18.GuidelineReus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101. PMID: 29301420.PMID: 29301420doi:10.1176/appi.ajp.2017.1750101
- 19.Systematic reviewMagill M, Ray L, Kiluk B, Hoadley A, Bernstein M, Tonigan JS, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093-1105. doi:10.1037/ccp0000447. PMID: 31599606.PMID: 31599606doi:10.1037/ccp0000447
- 20.Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Oxford: Wiley Blackwell; 2021.
- 21.Bates ME, Buckman JF, Nguyen TT. A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev. 2013;23(1):27-47. doi:10.1007/s11065-013-9228-3. PMID: 23412885.PMID: 23412885doi:10.1007/s11065-013-9228-3
- 22.Hanlon CA, Dowdle LT, Henderson JS. Modulating neural circuits with transcranial magnetic stimulation: implications for addiction treatment development. Pharmacol Rev. 2018;70(3):661-683. doi:10.1124/pr.116.013649. PMID: 29945898.PMID: 29945898doi:10.1124/pr.116.013649
More on these topics
Neurocognitive Disorder Due to Traumatic Brain Injury
A clinical reference on diagnosis, mechanisms, assessment, and management of major and mild neurocognitive disorder due to traumatic brain injury.
Neurocognitive Disorder Due to Traumatic Brain InjuryCognitive ImpairmentDifferential DiagnosisVascular Neurocognitive Disorder: Diagnosis, Subtypes, and Management
A clinical reference on vascular neurocognitive disorder covering DSM-5-TR criteria, vascular subtypes, assessment, and evidence-graded management.
Vascular Neurocognitive DisorderSpecial PopulationsNeurocognitive DisordersNeurocognitive Disorder Due to Lewy Body Disease (Dementia with Lewy Bodies)
Clinical reference on dementia with Lewy bodies: DSM-5-TR criteria, core features, neuroleptic sensitivity, and evidence-based management.
Neurocognitive DisordersGeriatric PsychiatryNeurocognitive Disorder Due to Lewy Body DiseaseFrontotemporal Neurocognitive Disorder: Clinical Features, Diagnosis, and Management
A clinical reference on frontotemporal neurocognitive disorder covering DSM-5-TR criteria, FTLD subtypes, differential diagnosis, and symptomatic management.
Neurocognitive DisordersGeriatric PsychiatryFrontotemporal Neurocognitive DisorderAlzheimer's Disease: Diagnosis, Pathophysiology, and Clinical Management
A clinician-oriented reference on Alzheimer's disease covering DSM-5-TR criteria, biomarker-based diagnosis, pharmacologic and non-pharmacologic management, and emerging anti-amyloid therapies.
Neurocognitive DisordersGeriatric PsychiatryAlzheimer's DiseaseMild Neurocognitive Disorder
DSM-5-TR mild neurocognitive disorder: diagnostic criteria, etiologic subtypes, assessment, and evidence-based management.
Neurocognitive DisordersGeriatric PsychiatryPrognosisMajor Neurocognitive Disorder (Dementia): Clinical Overview
A clinical reference on major neurocognitive disorder covering DSM-5-TR criteria, etiologic subtypes, assessment, evidence-based management, and prognosis.
Neurocognitive DisordersGeriatric PsychiatryAlzheimer's DiseaseDelirium
A practical clinical reference on delirium: recognition, workup, evidence-based management, and the harms of overusing antipsychotics and benzodiazepines.
Neurocognitive DisordersConsultation-Liaison PsychiatryGeriatric Psychiatry